Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AbbVie and Galapagos announce cystic fibrosis collaboration

AbbVie and Galapagos announce cystic fibrosis collaboration

1st October 2013

AbbVie has expanded its existing partnership with fellow healthcare company Galapagos to include a cystic fibrosis drug development alliance.

The new collaboration will focus on the discovery, development and commercialisation of novel potentiator and combination therapies in cystic fibrosis, with both companies set to contribute technologies and resources.

Research will target the main mutations in cystic fibrosis patients, including F508del and G551D, with the aim of initiating phase I studies of potential new therapies by the end of 2014.

Galapagos selected this hereditary chronic condition as the first orphan disease for which it is attempting to discover, develop and launch its own medicines in 2010.

Dr Jim Sullivan, vice-president for pharmaceutical discovery at AbbVie, said: "Our knowledge of the patient experience, combined with innovative advances in the understanding of disease etiology, offers the potential for new transformational treatments."

This comes after AbbVie allied with Ablynx on the development and commercialisation of a promising new inflammatory disease therapy last month.ADNFCR-8000103-ID-801644271-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.